Prosecution Insights
Last updated: November 19, 2026

Theravance Biopharma R&D IP LLC

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

Theravance Biopharma R&D IP LLC has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units, indicating that each active case has a separate examination setting.

VALENROD, YEVGENY is the busiest examiner, with 1 pending matter. Because no examiner or art unit contains multiple pending matters, centralized docket control should be paired with individualized claim and response analysis.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (67%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (33%)
§102 only1 (33%)
Double-patenting only1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VALENROD, YEVGENY 1 72.6% +25.0%
WARD, PAUL V 1 83.3% -12.2%
WESTERBERG, NISSA M 1 23.4% +37.1%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18496404 PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME WARD, PAUL V —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18127570 METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY WESTERBERG, NISSA M —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18443907 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS VALENROD, YEVGENY —
18127570 METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY WESTERBERG, NISSA M —

Top Art Units

Art UnitApps
1628 1
1622 1
1618 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18443907 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS VALENROD, YEVGENY 1628 DP Non-Final OA — Pending Feb 16, 2024
18496404 PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME WARD, PAUL V 1622 §102 Non-Final OA — Pending Oct 27, 2023
18127570 METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY WESTERBERG, NISSA M 1618 §103Other Final Rejection — Pending Mar 28, 2023

Managing Theravance Biopharma R&D IP LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Theravance Biopharma R&D IP LLC have?

Theravance Biopharma R&D IP LLC has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most Theravance Biopharma R&D IP LLC applications?

Yevgeny Valenrod has the most, with 1 of Theravance Biopharma R&D IP LLC's pending office actions.

What technology area are Theravance Biopharma R&D IP LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month